These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 28285924)

  • 1. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.
    Zhao XZ; Hymel D; Burke TR
    Bioorg Med Chem; 2017 Oct; 25(19):5041-5049. PubMed ID: 28285924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
    Scharow A; Knappe D; Reindl W; Hoffmann R; Berg T
    Chembiochem; 2016 Apr; 17(8):759-67. PubMed ID: 26634982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel and selective non-peptide inhibitors targeting the polo-box domain of polo-like kinase 1.
    Chen Y; Li Z; Liu Y; Lin T; Sun H; Yang D; Jiang C
    Bioorg Chem; 2018 Dec; 81():278-288. PubMed ID: 30170276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors.
    Yun T; Qin T; Liu Y; Lai L
    Eur J Med Chem; 2016 Nov; 124():229-236. PubMed ID: 27592392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
    Berg A; Berg T
    Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors.
    Zhao XZ; Tsuji K; Hymel D; Burke TR
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31014020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1.
    Ahn M; Han YH; Park JE; Kim S; Lee WC; Lee SJ; Gunasekaran P; Cheong C; Shin SY; Kim HY; Ryu EK; Murugan RN; Kim NH; Bang JK
    J Med Chem; 2015 Jan; 58(1):294-304. PubMed ID: 25347203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain.
    Yan F; Liu G; Chen T; Fu X; Niu MM
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31892137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1.
    Ryu S; Park JE; Ham YJ; Lim DC; Kwiatkowski NP; Kim DH; Bhunia D; Kim ND; Yaffe MB; Son W; Kim N; Choi TI; Swain P; Kim CH; Lee JY; Gray NS; Lee KS; Sim T
    J Med Chem; 2022 Feb; 65(3):1915-1932. PubMed ID: 35029981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors.
    Sakkiah S; Senese S; Yang Q; Lee KW; Torres JZ
    PLoS One; 2014; 9(7):e101405. PubMed ID: 25036740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.
    McInnes C; Estes K; Baxter M; Yang Z; Farag DB; Johnston P; Lazo JS; Wang J; Wyatt MD
    Mol Cancer Ther; 2012 Aug; 11(8):1683-92. PubMed ID: 22848093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor.
    Baxter M; Chapagai D; Craig S; Hurtado C; Varghese J; Nurmemmedov E; Wyatt MD; McInnes C
    ChemMedChem; 2020 Jun; 15(12):1058-1066. PubMed ID: 32232973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
    Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
    Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy.
    Shakil S; Baig MH; Tabrez S; Rizvi SMD; Zaidi SK; Ashraf GM; Ansari SA; Khan AAP; Al-Qahtani MH; Abuzenadah AM; Chaudhary AG
    Semin Cancer Biol; 2019 Jun; 56():47-55. PubMed ID: 29122685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pinning down the polo-box domain.
    Lee KS; Idle JR
    Chem Biol; 2008 May; 15(5):415-6. PubMed ID: 18482691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of d-amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1.
    Li Z; Zhang Z; Chen Y; Tang S; Lin T; Huang J; Li B; Jiang C
    Bioorg Chem; 2019 Apr; 85():534-540. PubMed ID: 30807896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs.
    Qian WJ; Park JE; Lim D; Park SY; Lee KW; Yaffe MB; Lee KS; Burke TR
    Chem Biol; 2013 Oct; 20(10):1255-64. PubMed ID: 24120332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
    Shan HM; Shi Y; Quan J
    ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
    Kumar M; Pydi SP; Sharma S; Singh TP; Kaur P
    J Mol Graph Model; 2014 Jun; 51():104-12. PubMed ID: 24879322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
    Reindl W; Strebhardt K; Berg T
    Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.